enGene Therapeutics Analyst Price Targets - Benzinga

enGene Therapeutics Inc

ENGNNASDAQ

Trade with Public

Trade with Public

$1.48

-0.055-3.59%

마지막 업데이트: Oct 30, 1:40 PM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

enGene Therapeutics Analyst Price Targets - Benzinga

enGene Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for enGene Therapeutics (ENGN).

Price Target Range — 11 Quarters

Analyst Consensus — 11 Analysts

1S.Buy

5Buy

4Hold

1Sell

Consensus RatingBuy# Analysts11Avg. Consensus PT$18Upside to Avg. PT+1123.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	Citizens	Silvan Turkcan	Maintained	Market Perform	—
Sep 8, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$4
Jun 18, 2026	Morgan Stanley	Judah Frommer	Downgrade	Equal-Weight→Underweight	—
Jun 16, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Cut	Buy	$6→$4
May 14, 2026	UBS	Colin Bristow	PT Cut	Neutral	$9→$2
May 8, 2026	Citizens	Silvan Turkcan	Downgrade	Market Outperform→Market Perform	—
May 8, 2026	Piper Sandler	Allison Bratzel	Downgrade	Overweight→Neutral	$7→$4
May 8, 2026	Guggenheim	Michael Schmidt	Downgrade	Buy→Neutral	—
May 8, 2026	Wells Fargo	Yanan Zhu	Downgrade	Overweight→Equal-Weight	$25→$2
May 8, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Cut	Buy	$25→$6
Apr 13, 2026	WBB Securities	Karen Sterling	Initiate	Buy	$22
Mar 11, 2026	Oppenheimer	Leland Gershell	PT Cut	Outperform	$33→$30
Mar 9, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$25
Nov 12, 2025	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$18→$19
Nov 12, 2025	Oppenheimer	Leland Gershell	PT Raise	Outperform	$30→$33
Nov 12, 2025	UBS	Colin Bristow	PT Raise	Neutral	$4→$10
Nov 12, 2025	Citizens	Silvan Tuerkcan	PT Raise	Market Outperform	$18→$21
Sep 12, 2025	Morgan Stanley	Jeffrey Hung	PT Cut	Overweight	$19→$18
Sep 12, 2025	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$25
Sep 8, 2025	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$25

Analyst Ratings News

PRO
Citizens Reiterates Market Perform on enGene Therapeuticsto Market Perform

Citizens analyst Silvan Turkcan reiterates enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Market Perform.

Benzinga Newsdesk

This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzinga's analyst ratings page.

Avi Kapoor

PRO
Morgan Stanley Downgrades enGene Therapeutics to Underweight

Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Underweight.

Benzinga Newsdesk

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey. See full list here.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $4

HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $6 to $4.

Benzinga Newsdesk

PRO
Citizens Downgrades enGene Therapeutics to Market Perform

Citizens analyst Silvan Turkcan downgrades enGene Therapeutics (NASDAQ:ENGN) from Market Outperform to Market Perform.

Benzinga Newsdesk